Fig. 2
From: MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
MYC-expression is increased following platinum treatment in vivo. A Schematic overview of experimental approach. B Kaplan–Meier plot showing that carboplatin and etoposide treatment significantly increases the survival in the RP mouse model of SCLC. ****p < 0.0001 Log-rank Mantel-Cox test. C representative immunohistochemical analysis of MYC expression in vehicle and carboplatin / etoposide (Pt / etop) (D) The % of MYC positive cells per tumor area in each tissue section was determined using the automated positive cell detection feature in QuPath for each animal in each cohort (n > 7 mice per cohort). ****P < 0.0001 students t-test